Irina Amitai

Ramat Gan, TA, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Cladribine-based salvage therapy in relapsed/refractory AML: A multicenter retrospective study.

Cladribine-based salvage therapy in relapsed/refractory AML: A multicenter retrospective study.

Journal: Leukemia research

Published: June 07, 2026

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

Journal: Annals of hematology

Published: January 29, 2026

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

Journal: Annals of hematology

Published: January 29, 2026

Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO).

Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO).

Journal: Oncology and therapy

Published: November 06, 2025

High Implementation Adherence to Lenalidomide in Multiple Myeloma.

High Implementation Adherence to Lenalidomide in Multiple Myeloma.

Journal: Cancers

Published: September 27, 2025

Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II study.

Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II study.

Journal: British journal of haematology

Published: March 08, 2025

Kundalini Yoga for Improving Patient-Reported Outcomes in Patients Diagnosed with Myelodysplastic Syndromes: A Pilot Study.

Kundalini Yoga for Improving Patient-Reported Outcomes in Patients Diagnosed with Myelodysplastic Syndromes: A Pilot Study.

Journal: Acta haematologica

Published: February 07, 2025

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.

Journal: Blood

Published: January 30, 2025

Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma.

Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: September 27, 2024

Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study.

Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study.

Journal: Blood advances

Published: June 17, 2024

Role of Autologous Transplant in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Triplets: A Systematic Review and Meta-Analysis.

Role of Autologous Transplant in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Triplets: A Systematic Review and Meta-Analysis.

Journal: Acta haematologica

Published: April 22, 2024

Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.

Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.

Journal: British journal of haematology

Published: March 27, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026